XML 38 R24.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

SIGNIFICANT ACCOUNTING POLICIES (Details) $ / shares in Units, $ in Thousands |  |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 29, 2022 | May 13, 2021 USD ($) | Jul. 23, 2018 USD ($) | Oct. 19, 2017 USD ($) | Oct. 31, 2015 | Jun. 30, 2024 USD ($) agreement $ / shares shares | Jun. 30, 2023 USD ($) shares | Mar. 31, 2023 USD ($) shares | Jun. 30, 2024 USD ($) agreement $ / shares shares | Jun. 30, 2023 USD ($) shares | Dec. 31, 2023 $ / shares | Feb. 27, 2023 USD ($) | Jul. 02, 2021 USD ($) $ / shares
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of global licensing and supply agreements | agreement |  |  |  |  |  | 2 |  |  | 2 |  |  |  |
Common Stock, Par or Stated Value Per Share | $ / shares |  |  |  |  |  | $ 0.001 |  |  | $ 0.001 |  | $ 0.001 |  |
Stock issuance proceeds |  |  |  |  |  |  |  |  |  | $ 23,954 |  |  |
Antidilutive securities excluded from computation of earnings per share, amount | shares |  |  |  |  |  | 31,744,960 | 1,896,733 |  | 31,791,645 | 16,158,086 |  |  |
ATM Shares |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued (in shares) | shares |  |  |  |  |  |  |  | 13,980,060 |  |  |  |  |
Common Stock, Par or Stated Value Per Share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.001
Sale of stock, maximum offering price |  |  |  |  |  | $ 6,400 |  |  | $ 6,400 |  |  | $ 20,000 | $ 20,000
Stock issuance proceeds |  |  |  |  |  |  |  | $ 20,000 |  |  |  |  |
2024 Notes |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate (as a percent) |  |  |  |  |  | 7.50% |  |  | 7.50% |  |  |  |
Minimum cash balance required |  |  |  |  |  | $ 7,500 |  |  | $ 7,500 |  |  |  |
Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement revenues and expenses sharing percentage |  |  |  |  | 100.00% |  |  |  |  |  |  |  |
Chiesi Agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Amount of milestone payment received |  |  |  |  |  |  | $ 20,000 |  | $ 20,000 |  |  |  |
Chiesi US Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Additional amounts payable to cover development costs |  |  | $ 20,000 |  |  |  |  |  |  |  |  |  |
Additional amount payable for achievement of regulatory and commercial milestones |  |  | $ 760,000 |  |  |  |  |  |  |  |  |  |
Chiesi US Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Payment on net sales percentage |  |  | 15.00% |  |  |  |  |  |  |  |  |  |
Chiesi US Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Payment on net sales percentage |  |  | 40.00% |  |  |  |  |  |  |  |  |  |
Chiesi Ex-US Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Additional amounts payable to cover development costs |  |  |  | $ 25,000 |  |  |  |  |  |  |  |  |
Agreement amendment payment receivable |  | $ 10,000 |  |  |  |  |  |  |  |  |  |  |
Change in amount receivable for achievement of regulatory and commercial milestones |  | $ 25,000 |  |  |  |  |  |  |  |  |  |  |
Additional amount payable for achievement of regulatory and commercial milestones |  |  |  | $ 320,000 |  |  |  |  |  |  |  |  |
Chiesi Ex-US Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Payment on net sales percentage |  |  |  | 15.00% |  |  |  |  |  |  |  |  |
Chiesi Ex-US Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Payment on net sales percentage |  |  |  | 35.00% |  |  |  |  |  |  |  |  |
Chiesi US Agreement and Chiesi Ex-US Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable payment receivable |  |  | $ 25,000 | $ 25,000 |  |  |  |  |  |  |  |  |
Fill/Finish Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Extended term of agreement | 7 years |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition The total amount payable to entity for the achievement of regulatory and commercial milestones. + References No definition available. + Details
Name: | plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount payable to the entity to cover development costs under agreement. + References No definition available. + Details
Name: | plx_AdditionalAmountsPayableToCoverDevelopmentCosts
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Agreement Amendment Payment Receivable + References No definition available. + Details
Name: | plx_AgreementAmendmentPaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones + References No definition available. + Details
Name: | plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative arrangement revenues and expense sharing percentage. + References No definition available. + Details
Name: | plx_CollaborativeArrangementRevenuesExpensesSharingPercentage
Namespace Prefix: | plx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Extended term of agreement. + References No definition available. + Details
Name: | plx_ExtendedTermOfAgreement
Namespace Prefix: | plx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum cash balance required to be maintained under long term debt agreements. + References No definition available. + Details
Name: | plx_MaintainOfMinimumCashBalance
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of milestone payment received upon achievement of certain milestone. + References No definition available. + Details
Name: | plx_MilestonePaymentReceived
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the number of global licensing and supply agreements. + References No definition available. + Details
Name: | plx_NumberOfGlobalLicensingAndSupplyAgreements
Namespace Prefix: | plx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the payment as a percentage of future net sales. + References No definition available. + Details
Name: | plx_PaymentOnNetSalesPercentage
Namespace Prefix: | plx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sale of stock, maximum offering price. + References No definition available. + Details
Name: | plx_SaleOfStockMaximumOfferingPrice
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | plx_SignificantAccountingPoliciesLineItems
Namespace Prefix: | plx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights. + References No definition available. + Details
Name: | plx_UpfrontNonrefundableNoncreditablePaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Contractual interest rate for funds borrowed, under the debt agreement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details
Name: | us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_BR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |